Examkin

Soru

Zorluk: ZorGynecologic Oncology

A 59-year-old postmenopausal woman with a family history of breast cancer and a recently confirmed BRCA1 pathogenic variant presents to her physician with early satiety, bloating, and increasing abdominal girth for the past month. Physical examination reveals a palpable, fixed, irregular left adnexal mass and a clinically detectable fluid wave indicating ascites. Arrange the following steps in the most appropriate chronological order for the diagnostic workup and standard management of this patient, from initial evaluation to post-remission therapy.

  1. 1Perform pelvic ultrasonography to characterize the adnexal mass and confirm the presence of ascites.
  2. 2Obtain a serum CA-125 level and a computed tomography (CT) scan of the chest, abdomen, and pelvis.
  3. 3Perform an exploratory laparotomy for maximal surgical cytoreduction (tumor debulking) and comprehensive staging.
  4. 4Administer systemic adjuvant intravenous platinum- and taxane-based combination chemotherapy.
  5. 5Initiate maintenance therapy with a poly (ADP-ribose) polymerase (PARP) inhibitor.

Cevap

The correct sequence is: Pelvic ultrasonography, followed by CT scan and CA-125, then Surgical cytoreduction, followed by Adjuvant chemotherapy, and concluding with PARP inhibitor maintenance.
The standard diagnostic and therapeutic pathway for suspected advanced ovarian cancer begins with transvaginal ultrasonography, which is the most sensitive initial imaging modality to characterize adnexal pathology. Following sonographic confirmation of a suspicious mass, a CT scan of the chest, abdomen, and pelvis along with serum CA-125 is necessary for pre-operative staging and assessing surgical resectability. The primary therapeutic intervention is then an exploratory laparotomy for maximal surgical cytoreduction (debulking), followed by adjuvant systemic platinum-based and taxane-based chemotherapy. Finally, in a patient with a confirmed BRCA mutation who has completed primary chemotherapy and achieved a response, maintenance therapy with a PARP inhibitor is indicated to substantially prolong progression-free survival.

Adım Adım Çözüm

1
Identify the most appropriate initial diagnostic test for a suspected adnexal mass.
Pelvic ultrasonography is placed first.
Ultrasound is the primary modality to characterize adnexal masses and determine the initial risk of malignancy based on sonographic architecture.
2
Determine the necessary preoperative evaluation for a highly suspicious adnexal mass with ascites.
CT of the chest, abdomen, and pelvis with serum CA-125 is placed second.
Cross-sectional imaging is required to evaluate the extent of intra-abdominal and extra-abdominal metastasis to plan for surgical resectability.
3
Identify the primary therapeutic intervention.
Exploratory laparotomy for maximal surgical cytoreduction is placed third.
Surgical debulking is the standard of care for the primary treatment of advanced ovarian cancer, unless the disease is deemed entirely unresectable.
4
Select the appropriate post-surgical management.
Adjuvant systemic chemotherapy is placed fourth.
Platinum- and taxane-based chemotherapy is universally indicated following cytoreduction to eliminate residual disease in advanced ovarian carcinoma.
5
Identify the role of targeted therapy based on the patient's specific genetic profile.
PARP inhibitor maintenance therapy is placed last.
Because the patient has a known BRCA1 mutation, PARP inhibitor therapy is indicated strictly as maintenance after the completion of primary chemotherapy.

Anahtar Kavram

The standard chronological management of advanced epithelial ovarian cancer involves initial ultrasound evaluation, preoperative CT staging, maximal surgical cytoreduction, adjuvant platinum-based chemotherapy, and targeted maintenance therapy for patients with a BRCA mutation.
Bu soruyu puanla

Konular

Gynecologic Oncology

Bu konudan daha fazla soru